

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

| Patient Information | | Prescriber Information | |
|---------------------|---|------------------------|-----------------|
| Patient Name | | Prescriber Name | |
| Address | | Address | |
| City State Zip | | City State Zip | |
| Main Phone | Alternate Phone | Phone | Fax |
| Social Security # | | Contact Person | |
| Date of Birth | <input type="checkbox"/> Male <input type="checkbox"/> Female | DEA # | NPI # License # |

| Clinical Information | | | |
|--|---|--|--|
| Diagnosis | | | ICD-10 |
| Prior Failed Meds: _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| Serum PSA Level | Date Obtained | Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs | Height <input type="checkbox"/> ft <input type="checkbox"/> in |
| Gleason Score | <input type="checkbox"/> Confirmed HRR Mutation | Has the patient had a bilateral orchiectomy? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the medication given in combination with androgen deprivation therapy? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Is the prostate cancer metastatic? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is there documented evidence of one or more metastatic bone lesions? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-resistant? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-sensitive? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Drug Allergies | | | Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing |

| Prescription Information | | | Qty | Refills |
|--|---|---|--|----------------------------------|
| <input type="checkbox"/> Afinitor® | <input type="checkbox"/> 2.5mg Tablets <input type="checkbox"/> 5mg Tablets <input type="checkbox"/> 7.5mg Tablets <input type="checkbox"/> 10mg Tablets | <input type="checkbox"/> Take 1 tablet by mouth once daily <input type="checkbox"/> Other: _____ | 28 Tablets | _____ |
| <input type="checkbox"/> Avastin® Biosimilars: <input type="checkbox"/> Mvasi® <input type="checkbox"/> Zirabev® | _____ mg/kg | <input type="checkbox"/> Infuse _____ mg intravenously over 90 minutes every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Eligard® | <input type="checkbox"/> 7.5mg Syringe (1 month supply) <input type="checkbox"/> 22.5mg Syringe (3 month supply) <input type="checkbox"/> 30mg Syringe (4 month supply) <input type="checkbox"/> 45mg Syringe (6 month supply) | <input type="checkbox"/> Administer 7.5mg subcutaneously once a month <input type="checkbox"/> Administer 22.5mg subcutaneously every 3 months <input type="checkbox"/> Administer 30mg subcutaneously every 4 months <input type="checkbox"/> Administer 45mg subcutaneously every 6 months | 1 Syringe 1 Syringe 1 Syringe 1 Syringe | _____ _____ _____ _____ |
| <input type="checkbox"/> Erleada® | <input type="checkbox"/> 60mg Tablets <input type="checkbox"/> 240mg Tablets | <input type="checkbox"/> Take 4 tablets (240mg) by mouth once daily <input type="checkbox"/> Take 1 tablet (240mg) by mouth once daily | 120 Tablets 30 Tablets | _____ _____ |
| <input type="checkbox"/> Firmagon® | <input type="checkbox"/> 120mg Vial <input type="checkbox"/> 80mg Vial | <input type="checkbox"/> Loading Dose: Administer 240mg given as two subcutaneous injections of 120mg each <input type="checkbox"/> Maintenance Dose: Administer 80mg subcutaneously every 28 days, starting on day 29 | 2 Vials 1 Vial | None _____ |
| <input type="checkbox"/> Other | | | | |

By signing this form, you are authorizing Kroger® Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payors with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted Date Prescriber's Signature (no stamps) Dispense As Written Date

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

| Patient Information | | Prescriber Information | |
|---------------------|---|------------------------|-----------------|
| Patient Name | | Prescriber Name | |
| Address | | Address | |
| City State Zip | | City State Zip | |
| Main Phone | Alternate Phone | Phone | Fax |
| Social Security # | | Contact Person | |
| Date of Birth | <input type="checkbox"/> Male <input type="checkbox"/> Female | DEA # | NPI # License # |

| Clinical Information | | | |
|--|---|--|--|
| Diagnosis | | | ICD-10 |
| Prior Failed Meds: _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| Serum PSA Level | Date Obtained | Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs | Height <input type="checkbox"/> ft <input type="checkbox"/> in |
| Gleason Score | <input type="checkbox"/> Confirmed HRR Mutation | Has the patient had a bilateral orchiectomy? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the medication given in combination with androgen deprivation therapy? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Is the prostate cancer metastatic? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is there documented evidence of one or more metastatic bone lesions? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-resistant? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-sensitive? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Drug Allergies | | | Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing |

| Prescription Information | | | Qty | Refills |
|--|--|--|--|--|
| <input type="checkbox"/> Inlyta* | <input type="checkbox"/> 1mg Tablets <input type="checkbox"/> 5mg Tablets | <input type="checkbox"/> Take 1 tablet by mouth twice daily <input type="checkbox"/> Other: _____ | 60 Tablets | _____ |
| <input type="checkbox"/> Keytruda* | _____ mg | <input type="checkbox"/> Infuse _____ mg intravenously every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Lenvima* | <input type="checkbox"/> 4mg Daily Dose <input type="checkbox"/> 8mg Daily Dose <input type="checkbox"/> 10mg Daily Dose <input type="checkbox"/> 12mg Daily Dose <input type="checkbox"/> 14mg Daily Dose <input type="checkbox"/> 18mg Daily Dose <input type="checkbox"/> 20mg Daily Dose <input type="checkbox"/> 24mg Daily Dose | <input type="checkbox"/> Take one capsule (4mg) by mouth once daily <input type="checkbox"/> Take two 4mg capsules (8mg total) by mouth once daily <input type="checkbox"/> Take one capsule (10mg) by mouth once daily <input type="checkbox"/> Take three 4mg capsules (12mg total) by mouth once daily <input type="checkbox"/> Take one 4mg capsule and one 10mg capsule (14mg total) by mouth once daily <input type="checkbox"/> Take two 4mg capsules and one 10mg capsule (18mg total) by mouth once daily <input type="checkbox"/> Take two 10mg capsules (20mg total) by mouth once daily <input type="checkbox"/> Take two 10mg capsules and one 4mg capsule (24mg total) by mouth once daily <input type="checkbox"/> Other: _____ | 30 Capsules 60 Capsules 30 Capsules 90 Capsules 60 Capsules 90 Capsules 60 Capsules 90 Capsules | _____ _____ _____ _____ _____ _____ _____ _____ |
| <input type="checkbox"/> Lupron Depot* | <input type="checkbox"/> 7.5mg Syringe (1 month supply) <input type="checkbox"/> 22.5mg Syringe (3 month supply) <input type="checkbox"/> 30mg Syringe (4 month supply) <input type="checkbox"/> 45mg Syringe (6 month supply) | <input type="checkbox"/> Administer 7.5mg intramuscularly once a month <input type="checkbox"/> Administer 22.5mg intramuscularly every 3 months <input type="checkbox"/> Administer 30mg intramuscularly every 4 months <input type="checkbox"/> Administer 45mg intramuscularly every 6 months | 1 Syringe 1 Syringe 1 Syringe 1 Syringe | _____ _____ _____ _____ |
| <input type="checkbox"/> Nexavar* (sorafenib) *Generic only | 200mg Tablets | <input type="checkbox"/> Take 2 tablets (400mg) by mouth twice daily <input type="checkbox"/> Other: _____ | 120 Tablets | _____ |
| <input type="checkbox"/> Nilandron* | 150mg Tablets | <input type="checkbox"/> Initial: Take 2 tablets (300mg total) by mouth once daily for 30 days <input type="checkbox"/> Maintenance: Take 1 tablet by mouth once daily | 60 Tablets 30 Tablets | None _____ |
| <input type="checkbox"/> Opdivo* | _____ mg/kg | <input type="checkbox"/> Infuse _____ mg intravenously over 30 minutes every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Other | | | | |

By signing this form, you are authorizing Kroger Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payors with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps)

Dispense As Written

Date

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

| Patient Information | | Prescriber Information | |
|---------------------|---|------------------------|-----------------|
| Patient Name | | Prescriber Name | |
| Address | | Address | |
| City State Zip | | City State Zip | |
| Main Phone | Alternate Phone | Phone | Fax |
| Social Security # | | Contact Person | |
| Date of Birth | <input type="checkbox"/> Male <input type="checkbox"/> Female | DEA # | NPI # License # |

| Clinical Information | | | |
|--|---|--|--|
| Diagnosis | | | ICD-10 |
| Prior Failed Meds: _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| _____ | | Length of Treatment: _____ Reason for Discontinuing: _____ | |
| Serum PSA Level | Date Obtained | Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs | Height <input type="checkbox"/> ft <input type="checkbox"/> in |
| Gleason Score | <input type="checkbox"/> Confirmed HRR Mutation | Has the patient had a bilateral orchiectomy? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the medication given in combination with androgen deprivation therapy? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Is the prostate cancer metastatic? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is there documented evidence of one or more metastatic bone lesions? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-resistant? <input type="checkbox"/> No <input type="checkbox"/> Yes | Is the prostate cancer castration-sensitive? <input type="checkbox"/> No <input type="checkbox"/> Yes |
| Drug Allergies | | | Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing |

| Prescription Information | | | Qty | Refills |
|---|--|--|---|---------|
| <input type="checkbox"/> Sutent® | <input type="checkbox"/> 12.5mg Capsules <input type="checkbox"/> 25mg Capsules <input type="checkbox"/> 37.5mg Capsules <input type="checkbox"/> 50mg Capsules | <input type="checkbox"/> Take 1 capsule by mouth once daily for 4 weeks on-treatment, followed by 2 weeks off-treatment <input type="checkbox"/> Other: _____ | 28 Capsules | _____ |
| <input type="checkbox"/> Tecentriq® | _____ mg | <input type="checkbox"/> Infuse _____ mg intravenously over 60 minutes every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Torisel® | 25mg/mL Vial | <input type="checkbox"/> Infuse _____ mg intravenously over 30 to 60 minutes every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Trelstar® | <input type="checkbox"/> 3.75mg Mixject <input type="checkbox"/> 11.25mg Mixject <input type="checkbox"/> 22.5mg Mixject | <input type="checkbox"/> Administer 3.75mg intramuscularly once every 4 weeks <input type="checkbox"/> Administer 11.25mg intramuscularly once every 12 weeks <input type="checkbox"/> Administer 22.5mg intramuscularly once every 24 weeks | 1 Inj. Suspension 1 Inj. Suspension 1 Inj. Suspension | _____ |
| <input type="checkbox"/> Votrient® | 200mg Tablet | <input type="checkbox"/> Take 4 tablets (800mg) by mouth once daily without food (at least 1 hour before or 2 hours after a meal) <input type="checkbox"/> Other: _____ | 120 Tablets | _____ |
| <input type="checkbox"/> Xgeva® | 120mg/1.7mL Vial | Inject 120mg subcutaneously once every 4 weeks | 1 Vial | _____ |
| <input type="checkbox"/> Xtandi® | <input type="checkbox"/> 40mg Capsules <input type="checkbox"/> 40mg Tablets <input type="checkbox"/> 80mg Tablets | <input type="checkbox"/> Take 4 capsules (160mg) by mouth once daily <input type="checkbox"/> Take 4 tablets (160mg) by mouth once daily <input type="checkbox"/> Take 2 tablets (160mg) by mouth once daily | 120 Capsules 120 Tablets 60 Tablets | _____ |
| <input type="checkbox"/> Yervoy® | _____ mg/kg | <input type="checkbox"/> Infuse _____ mg intravenously over 30 minutes every _____ days <input type="checkbox"/> Other: _____ | #QS _____ days | _____ |
| <input type="checkbox"/> Yonsa® <i>*Prescribe Methylprednisolone below, as needed</i> | 125mg Tablets | Take 4 tablets (500mg) by mouth once daily | 120 Tablets | _____ |
| <input type="checkbox"/> Zoladex® | <input type="checkbox"/> 3.6mg Implant Syringe (1 month supply) <input type="checkbox"/> 10.8mg Implant Syringe (3 month supply) | | | _____ |
| <input type="checkbox"/> Zytiga® <i>*Prescribe Prednisone below, as needed</i> | <input type="checkbox"/> 250mg Tablets <input type="checkbox"/> 500mg Tablets | <input type="checkbox"/> Take 4 tablets (1000mg) by mouth once daily on an empty stomach <input type="checkbox"/> Take 2 tablets (1000mg) by mouth once daily on an empty stomach | 120 Tablets 60 Tablets | _____ |
| Supportive Therapies <input type="checkbox"/> Casodex® <input type="checkbox"/> Methylprednisolone <input type="checkbox"/> Prednisone | 50mg Tablets 4mg Tablets 5mg Tablets | Take 1 tablet by mouth once daily Take 1 tablet by mouth twice daily with food Take 1 tablet by mouth twice daily with food | 30 Tablets 60 Tablets 60 Tablets | _____ |
| <input type="checkbox"/> Other | | | | _____ |

By signing this form, you are authorizing Kroger Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payors with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted Date Prescriber's Signature (no stamps) Dispense As Written Date